Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension

OBJECTIVE: To report the efficacy and safety of upadacitinib through 1 year in patients with ankylosing spondylitis (AS). METHODS: In the SELECT‐AXIS 1 study, adults with active AS and an inadequate response to nonsteroidal antiinflammatory drugs were randomized to receive upadacitinib 15 mg once da...

Descripción completa

Detalles Bibliográficos
Autores principales: Deodhar, Atul, van der Heijde, Désirée, Sieper, Joachim, Van den Bosch, Filip, Maksymowych, Walter P., Kim, Tae‐Hwan, Kishimoto, Mitsumasa, Ostor, Andrew, Combe, Bernard, Sui, Yunxia, Chu, Alvina D., Song, In‐Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299108/
https://www.ncbi.nlm.nih.gov/pubmed/34196498
http://dx.doi.org/10.1002/art.41911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299108/
https://www.ncbi.nlm.nih.gov/pubmed/34196498
http://dx.doi.org/10.1002/art.41911

Ejemplares similares